Literature DB >> 10581078

Reversal of virus-induced systemic shock and respiratory failure by blockade of the lymphotoxin pathway.

M T Puglielli1, J L Browning, A W Brewer, R D Schreiber, W J Shieh, J D Altman, M B Oldstone, S R Zaki, R Ahmed.   

Abstract

At present, little is known about the pathogenesis of acute virus-induced shock and pulmonary failure. A chief impediment in understanding the underlying disease mechanisms and developing treatment strategies has been the lack of a suitable animal model. This study describes a mouse model of virus-induced systemic shock and respiratory distress, and shows that blockade of the lymphotoxin beta receptor pathway reverses the disease.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10581078     DOI： 10.1038/70938

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


  20 in total

1.  A role for surface lymphotoxin in experimental autoimmune encephalomyelitis independent of LIGHT.

Authors:  Jennifer L Gommerman; Keith Giza; Stuart Perper; Irene Sizing; Apinya Ngam-Ek; Cheryl Nickerson-Nutter; Jeffrey L Browning
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

Review 2.  Role of lymphotoxin in experimental models of infectious diseases: potential benefits and risks of a therapeutic inhibition of the lymphotoxin-beta receptor pathway.

Authors:  Thomas W Spahn; Hans-Pietro Eugster; Adriano Fontana; Wolfram Domschke; Torsten Kucharzik
Journal:  Infect Immun       Date:  2005-11       Impact factor: 3.441

Review 3.  LIGHT-related molecular network in the regulation of innate and adaptive immunity.

Authors:  Yanhui Xu; Koji Tamada; Lieping Chen
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

Review 4.  Targeting lymphocyte activation through the lymphotoxin and LIGHT pathways.

Authors:  Carl F Ware
Journal:  Immunol Rev       Date:  2008-06       Impact factor: 12.988

5.  LTβR signaling in dendritic cells induces a type I IFN response that is required for optimal clonal expansion of CD8+ T cells.

Authors:  Leslie Summers deLuca; Dennis Ng; Yunfei Gao; Michael E Wortzman; Tania H Watts; Jennifer L Gommerman
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-18       Impact factor: 11.205

6.  Type I interferon is a therapeutic target for virus-induced lethal vascular damage.

Authors:  Roberto Baccala; Megan J Welch; Rosana Gonzalez-Quintial; Kevin B Walsh; John R Teijaro; Anthony Nguyen; Cherie T Ng; Brian M Sullivan; Alessandro Zarpellon; Zaverio M Ruggeri; Juan Carlos de la Torre; Argyrios N Theofilopoulos; Michael B A Oldstone
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-02       Impact factor: 11.205

7.  Identification of a Locus in Mice that Regulates the Collateral Damage and Lethality of Virus Infection.

Authors:  Ichiro Misumi; Kevin D Cook; Joseph E Mitchell; Makayla M Lund; Sarah C Vick; Robert H Lee; Toru Uchimura; Wolfgang Bergmeier; Piotr Mieczkowski; Fernando Pardo-Manuel de Villena; Jenny P Y Ting; Jason K Whitmire
Journal:  Cell Rep       Date:  2019-04-30       Impact factor: 9.423

Review 8.  Lymphotoxin in physiology of lymphoid tissues - Implication for antiviral defense.

Authors:  Ekaterina P Koroleva; Yang-Xin Fu; Alexei V Tumanov
Journal:  Cytokine       Date:  2016-09-09       Impact factor: 3.861

9.  Elevated generation of reactive oxygen/nitrogen species in hantavirus cardiopulmonary syndrome.

Authors:  Ian C Davis; Allan J Zajac; Kurt B Nolte; Jason Botten; Brian Hjelle; Sadis Matalon
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

10.  Effective Treatment of Experimental Lymphocytic Choriomeningitis Virus Infection: Consideration of Favipiravir for Use With Infected Organ Transplant Recipients.

Authors:  Brady T Hickerson; Jonna B Westover; Kie-Hoon Jung; Takashi Komeno; Yousuke Furuta; Brian B Gowen
Journal:  J Infect Dis       Date:  2018-07-13       Impact factor: 5.226
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.